Blood test guides next move against stubborn colon cancer

NCT ID NCT04920032

First seen Apr 21, 2026 · Last updated Apr 30, 2026 · Updated 2 times

Summary

This study tests a new approach for people with colon cancer that shows signs of remaining after surgery and standard chemotherapy. Using a blood test that detects tiny bits of tumor DNA (ctDNA), doctors will switch patients to a combination of two drugs (TAS-102 and irinotecan) to try to eliminate the leftover cancer. The goal is to see if this ctDNA-guided change in treatment can clear the cancer and prevent it from coming back. About 22 adults with stage II-IV colon cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.